Literature DB >> 35905755

Predicting COPD Progression in Current and Former Smokers Using a Joint Model for Forced Expiratory Volume in 1 Second and Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio.

Matthew Strand1, Aastha Khatiwada1, David Baraghoshi1, David Lynch2, Edwin K Silverman3, Surya P Bhatt4, Erin Austin5, Elizabeth A Regan6, Aladin M Boriek7, James D Crapo6.   

Abstract

Understanding baseline characteristics that can predict the progression of lung disease such as chronic obstructive pulmonary disease (COPD) for current or former smokers may allow for therapeutic intervention, particularly for individuals at high risk of rapid disease progression or transition from non-COPD to COPD. Classic diagnostic criteria for COPD and disease severity such as the Global Initiative for Chronic Obstructive Lung Disease document are based on forced expiratory volume in 1 second (FEV1) and FEV1 to forced vital capacity (FVC) ratio. Modeling changes in these outcomes jointly is beneficial given that they are correlated, and they are both required for specific disease classifications. Here, linear mixed models were used to model changes in FEV1 and FEV1/FVC jointly for 5- and 10-year intervals, using important baseline predictors to better understand the factors that affect disease progression. Participants with predicted loss of FEV1 and/or FEV1/FVC of at least 5% tended to have more emphysema, higher functional residual capacity, higher airway wall thickness as measured by Pi10, lower FVC to total lung capacity ratio and a lower body mass index at baseline, all relative to overall cohort averages. The model developed can be used to predict progression for any potential COPD individual, based on demographic, symptom, computed tomography, and comorbidity variables. JCOPDF
© 2022.

Entities:  

Keywords:  COPDGene; GOLD; PRISm; linear mixed model; preserved ratio-impaired spirometry; spirometry

Year:  2022        PMID: 35905755      PMCID: PMC9448007          DOI: 10.15326/jcopdf.2022.0281

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  19 in total

1.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

3.  Airway wall thickness associated with forced expiratory volume in 1 second decline and development of airflow limitation.

Authors:  Firdaus A A Mohamed Hoesein; Pim A de Jong; Jan-Willem J Lammers; Willem P T M Mali; Michael Schmidt; Harry J de Koning; Carlijn van der Aalst; Matthijs Oudkerk; Rozemarijn Vliegenthart; Harry J M Groen; Bram van Ginneken; Eva M van Rikxoort; Pieter Zanen
Journal:  Eur Respir J       Date:  2015-01-22       Impact factor: 16.671

4.  Chest wall strapping increases expiratory airflow and detectable airway segments in computer tomographic scans of normal and obstructed lungs.

Authors:  Hisham Taher; Christian Bauer; Eric Abston; David W Kaczka; Surya P Bhatt; Joseph Zabner; Roy G Brower; Reinhard R Beichel; Michael Eberlein
Journal:  J Appl Physiol (1985)       Date:  2018-01-04

5.  Effect of obesity on respiratory mechanics during rest and exercise in COPD.

Authors:  Josuel Ora; Pierantonio Laveneziana; Karin Wadell; Megan Preston; Katherine A Webb; Denis E O'Donnell
Journal:  J Appl Physiol (1985)       Date:  2011-02-24

6.  A Risk Prediction Model for Mortality Among Smokers in the COPDGene® Study.

Authors:  Matthew Strand; Erin Austin; Matthew Moll; Katherine A Pratte; Elizabeth A Regan; Lystra P Hayden; Surya P Bhatt; Aladin M Boriek; Richard Casaburi; Edwin K Silverman; Spyridon Fortis; Ingo Ruczinski; Harald Koegler; Harry B Rossiter; Mariaelena Occhipinti; Nicola A Hanania; Hirut T Gebrekristos; David A Lynch; Ken M Kunisaki; Kendra A Young; Jessica C Sieren; Margaret Ragland; John E Hokanson; Sharon M Lutz; Barry J Make; Gregory L Kinney; Michael H Cho; Massimo Pistolesi; Dawn L DeMeo; Frank C Sciurba; Alejandro P Comellas; Alejandro A Diaz; Igor Barjaktarevic; Russell P Bowler; Richard E Kanner; Stephen P Peters; Victor E Ortega; Mark T Dransfield; James D Crapo
Journal:  Chronic Obstr Pulm Dis       Date:  2020-10

7.  FEV1 is a better predictor of mortality than FVC: the PLATINO cohort study.

Authors:  Ana Maria B Menezes; Rogelio Pérez-Padilla; Fernando César Wehrmeister; Maria Victorina Lopez-Varela; Adriana Muiño; Gonzalo Valdivia; Carmen Lisboa; José Roberto B Jardim; Maria Montes de Oca; Carlos Talamo; Renata Bielemann; Mariana Gazzotti; Ruy Laurenti; Bartolomé Celli; Cesar G Victora
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

Review 8.  Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.

Authors:  Karin J C Sanders; Anita E M Kneppers; Coby van de Bool; Ramon C J Langen; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-09-07       Impact factor: 12.910

9.  FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease.

Authors:  Andras Bikov; Peter Lange; Julie A Anderson; Robert D Brook; Peter M A Calverley; Bartolome R Celli; Nicholas J Cowans; Courtney Crim; Ian J Dixon; Fernando J Martinez; David E Newby; Julie C Yates; Jørgen Vestbo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-05-20

10.  BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials.

Authors:  Yilan Sun; Stephen Milne; Jen Erh Jaw; Chen Xi Yang; Feng Xu; Xuan Li; Ma'en Obeidat; Don D Sin
Journal:  Respir Res       Date:  2019-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.